CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Results of Operations and Financial Condition
The information set forth under this “Item 2.02. Results of Operations and Financial Condition,” including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Attached as Exhibit 99.1 is a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “Company”), dated August 13, 2019, announcing certain financial results for the second quarter ended June 30, 2019.
The Company will conduct a conference call to review its financial results on August 13, 2019, at 4:30 p.m., Eastern Time.
|99.1||Press release announcing financial results for the second quarter ended June 30, 2019, dated August 13, 2019.|
Cyclacel Pharmaceuticals, Inc. Exhibit
EX-99.1 2 tv527489_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cyclacel Pharmaceuticals,…
To view the full exhibit click
About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.